What is Mirati Therapeutics' stock symbol?
Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."
Where is Mirati Therapeutics' stock going? Where will Mirati Therapeutics' stock price be in 2017?
9 equities research analysts have issued twelve-month target prices for Mirati Therapeutics' shares. Their predictions range from $5.00 to $32.00. On average, they expect Mirati Therapeutics' stock price to reach $16.11 in the next twelve months.
When will Mirati Therapeutics announce their earnings?
Mirati Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.
What are analysts saying about Mirati Therapeutics stock?
Here are some recent quotes from research analysts about Mirati Therapeutics stock:
Jefferies Group LLC analysts commented, "MRTX reported clinical updates on lead programs, glesatinib and sitravatinib. ID’ing glesatinib’s optimal patient pop (MET amp) as well as better safety w/ lower discontinuation rate on new formulation could start to pay off as more pts enter ph.II, which could help enable them to show whether activity is differentiated. Sitravatinib data remains early." (1/9/2017)
According to Zacks Investment Research, "Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. " (1/5/2017)
Who owns Mirati Therapeutics stock?
Mirati Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Aviva Holdings Ltd. (10.00%), Broadfin Capital LLC (4.15%), Boxer Capital LLC (3.80%), Franklin Resources Inc. (1.90%), State Street Corp (0.95%) and RTW Investments LP (0.65%). Company insiders that own Mirati Therapeutics stock include Boxer Capital, Llc, Bros Advisors Lp Baker, Charles M Baum, Jamie Christensen, Ltd Braslyn and Mark J Gergen.
Who sold Mirati Therapeutics stock? Who is selling Mirati Therapeutics stock?
Mirati Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Broadfin Capital LLC and AQR Capital Management LLC.
Who bought Mirati Therapeutics stock? Who is buying Mirati Therapeutics stock?
Mirati Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Trexquant Investment LP and RTW Investments LP. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc, Bros Advisors Lp Baker, Charles M Baum and Ltd Braslyn.
How do I buy Mirati Therapeutics stock?
Shares of Mirati Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Mirati Therapeutics stock cost?
One share of Mirati Therapeutics stock can currently be purchased for approximately $5.75.